To the question of thrombotic and hemorrhagic complications in patients with COVID-19

Author:

Glushkov N. I.1ORCID,Puzdriak P. D.1ORCID,Zvyagintseva A. N.1ORCID,Panasyuk E. I.1ORCID,Gavrilov V. Yu.1ORCID,Ivanov M. A.1ORCID,Zhdanovich K. V.1ORCID

Affiliation:

1. Northwestern State Medical University named after. I. I. Mechnikov of Minzdrav of Russia

Abstract

COVID-19 is characterized by various adverse consequences and complications, the prevention of which affects the outcome of the disease. Aim of the study was to investigate the thrombohemorrhagic events of COVID-19 infection. Material and methods. This study involved 403 patients with novel coronavirus infection; the patients were divided into 2 groups: 75 with COVID-19 complications and 328 patients without complications. Metabolic disorders, features of lung damage, comorbidity, signs of inflammation and coagulation, treatment outcomes, peculiarities of thrombotic events and hemorrhages development were studied. Results and its discussion. Thrombohemorrhagic complications of COVID-19 occurred mostly in patients with angina pectoris, coronary artery sclerosis and chronic heart failure of functional class II–III, as well as decompensated diabetes mellitus and obesity. These coronavirus infection effects are often accompanied by an increase in content of inflammatory markers such as CRP and ferritin, as well as of hypercoagulability (D-dimers). Conclusions. Manifestations of inflammatory coagulopathy in patients infected by COVID-19 increases risk of thrombohemorrhagic complications.

Publisher

Institute of Cytology and Genetics, SB RAS

Reference16 articles.

1. Глушков Н.И., Иванов М.А., Апресян А.Ю., Пуздряк П.Д., Артемова А.С. Влияние метаболического синдрома на исходы реконструкций у больных с инфраингвинальной артериальной болезнью. Вестн. Сев.-Зап. гос. мед. ун-та им. И.И. Мечникова. 2018;10(3:):54–59. doi: 10.17816/mechnikov201810354-59

2. Лебедева А.А., Куликов А.Н., Ковальчук Ю.П., Кадинская М.И., Гинзбург А.М., Власов Т.Д. Эндотелиальная дисфункция и тромботические события у больных с тяжелым течением новой коронавирусной инфекции COVID-19. Учен. зап. Первого СПбГМУ. 2021;28(4):38–47. doi: 10.24884/1607-4181-2021-28-4-38-47

3. Макацария А.Д., Слуханчук Е.В., Бицадзе В.О., Хизроева Д.Х., Третьякова М.В., Шкода А.С., Элалами И., Ди Ренцо Д., Риццо Д., Пятигорская Н.В., … Митрюк Д.В. Влияние различных видов антикоагулянтной терапии на снижение летальности при COVID-19. Вестн. РАМН. 2021;76(3):268–278. doi: 10.15690/vramn1551

4. Временные рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 10 (08.02.2021). Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/Временные_МР_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf.

5. Федотова Е.В., Чупров В.А., Чупрова А.А., Попов В.А., Хидиятов И.И., Авалиани В.М., Анкудинова И.С. Особенности тромбозов у пациентов с новой коронавирусной инфекцией COVID-19. Междунар. научно-исслед. ж. 2023;(1):127. doi: 10.23670/IRJ.2023.127.6

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3